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To better understand the molecular epidemiology of tuberculosis (TB) transmission for culture-confirmed
patients <5 years of age, data were analyzed from a population-based study conducted in seven U.S. sites
from 1996 to 2000. Mycobacterium tuberculosis isolates were genotyped with IS6110-based restriction
fragment length polymorphism analysis and spoligotyping. Case-patient data were obtained from the Cen-
ters for Disease Control and Prevention’s national tuberculosis registry and health department records.
Routine public health investigations conducted by local health departments identified suspected source
patients for 57 (51%) of 111 culture-confirmed patients <5 years of age. For 8 (15%) of 52 culture-con-
firmed patients <5 years of age and their suspected source patients with complete genotyping results, gen-
otypes suggested infection with different TB strains. Potential differences between sources for patients <5
years of age and source patients that transmitted TB to adolescent and adult patients were identified. 
he occurrence of tuberculosis (TB) in children is an indi-
cator of ongoing Mycobacterium tuberculosis transmis-
sion and of deficiencies in current public health efforts. In the
United States, strategies to prevent childhood TB include iden-
tifying and promptly initiating treatment for adults with active
TB to interrupt transmission (1–4). Since children have an
increased risk for developing severe disease within weeks to
months of infection, they are high priorities when identified as
contacts to infectious patients (5,6).
For newly diagnosed TB in children, source-case investi-
gations are conducted to ascertain the source of infection and
to prevent ongoing transmission from infectious persons.
Despite efforts by TB-control programs, suboptimal numbers
of source patients are identified for children (7–12). Pinpoint-
ing the source of TB infection may be particularly challenging
when numerous exposures exist, including contact with per-
sons who reside outside the United States (13). Failure to find
the true source patient may have treatment implications; deci-
sions about the treatment regimen for children often hinge on
the drug-susceptibility results of the suspected source patient
because cultures from young children are often not available
or attempts are not made to obtain these cultures (14). 
The use of molecular analysis with conventional epidemi-
ology has increased our understanding of TB transmission
(15,16). In outbreaks and population-based studies, genotyp-
ing has been instrumental in identifying previously unsus-
pected connections among TB patients (17). Genotyping has
also been used to evaluate epidemiologic links established
through contact investigations. One report found that more
than one quarter of index patients and their contacts who had
TB and shared a household were infected with different TB
strains, indicating that transmission did not occur between the
household contacts (18). 
In 1996, the Centers for Disease Control and Prevention
(CDC) established the National Tuberculosis Genotyping and
Surveillance Network (genotyping network) to conduct popu-
lation-based genotyping in seven U.S. sentinel surveillance
sites (19). During a 5-year period, the network collected infor-
mation on culture-confirmed patients and their contacts with
TB who were identified through routine public health investi-
gations. Study sites also attempted to collect and genotype at
least one M. tuberculosis isolate from each reported culture-
confirmed case in the surveillance area.
To better understand the molecular epidemiology of TB
transmission among young children (patients <5 years of age),
data collected by the genotyping network were analyzed to
report the frequency that suspected source patients were iden-
tified for young children, to examine the frequency and char-
acteristics of source patients for young children, and to
determine the proportion of isolates from young children and
their identified source patients with discordant genotypes. We
also investigated potential differences in the characteristics of
source patients who transmitted TB to young children as com-
pared to source patients who transmitted to adolescent and
adult patients.
Methods
Collection of Epidemiologic Data
A detailed description of study participants, population,
and methodology is reported elsewhere (20). In brief, health
department records were reviewed for all culture-confirmed
patients who met the surveillance case definition (21) and
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were reported from the seven sites (Arkansas, California [six
counties], Maryland, Massachusetts, Michigan, New Jersey,
and Texas [four counties]) from January 1996 through Decem-
ber 2000. Contacts (of culture-confirmed patients in the senti-
nel areas) with active TB were identified through routine
public health investigations, as defined by local contact and
source-case investigation policies and practices at each study
site. Source case investigations were undertaken for all
patients <5 years of age. Two sites also routinely performed
source case investigations on children >5 years of age. Infor-
mation about epidemiologically related patients identified
from public health investigations was gathered with a stan-
dardized data collection form that included the direction of
transmission (i.e., whether the contact was a source patient or
secondary patient in relation to the index patient or whether
the direction of transmission was unknown), the relationship
between patients (shared a household, nonhousehold friends or
relatives, co-worker, or common source), and the exposure set-
ting (correctional, school or day-care center, workplace, emer-
gency shelter, group quarters, hospital, nursing home, other
long-term care facility, or other setting). Data were entered
into Epi Info version 6d (22) databases and routinely sent to
CDC. State TB registry numbers for patients in the multisite
genotyping network database were matched against the CDC’s
national TB surveillance registry to obtain sociodemographic,
behavioral, clinical, treatment, and drug-susceptibility infor-
mation, which is routinely reported for all TB patients on the
Report of Verified Patients of Tuberculosis (23). Project activ-
ities described in this paper were determined by CDC’s institu-
tional review board to be exempt from full committee review
since genotyping of isolates was considered a public health
surveillance activity and all other data used in the analysis of
this paper were previously collected. 
DNA Fingerprinting
Genotyping of M. tuberculosis isolates was conducted in
accordance with standardized study protocols (20). IS6110-
based restriction fragment length polymorphism (RFLP) anal-
ysis was performed on all available isolates. Because low-copy
numbers of IS6110 reduce test specificity, isolates containing
six or fewer IS6110 copies were further analyzed by spacer
oligonucleotide typing (spoligotyping) (24). Patients were
determined to have concordant genotypes if their isolates con-
tained seven or more IS6110 bands with identical patterns or
six or fewer IS6110 bands with identical patterns and matching
spoligotypes. 
Study Case Definitions
Our investigation focused on culture-confirmed patients
<5 years of age; TB in young children represents recent trans-
mission, and source patient investigations are routinely con-
ducted for this group. A source patient was defined as a
confirmed TB patient who was identified by chart abstraction
as the likely source of infection for another reported TB
patient. A secondary patient was defined as a confirmed TB
patient who was infected by an identifiable source. Epidemio-
logically related source patients and secondary patients identi-
fied through routine public health investigations were
considered suspected patient pairs. Because some source
patients transmitted TB to more than one secondary patient,
the number of suspected patient pairs does not equal the num-
ber of source patients. A secondary patient, however, could
have only one designated source patient. 
Genotypes for isolates from suspected patient pairs were
compared, and patient pairs were categorized as 1) confirmed
patient pairs, if isolates had concordant genotypes, 2) refuted
patient pairs, if isolates had discordant genotypes, and 3) unde-
termined patient pairs, if genotypes were unavailable for the
patient pair. 
Data Analysis
Data in the multisite genotyping network database were
analyzed with SAS version 8.0 (25) and Epi Info version 6d
(22) software packages. Patients were excluded from analysis
when records were not available for review or lacked complete
information from public health investigations, including three
patients <5 years of age from one site, for whom source
patients were not identified but who were entered into the
database as the source for an adult case. Because young chil-
dren are not typically considered to be infectious (26) and
records for these patients were not available for further exami-
nation at the time of this analysis, information was determined
to be incomplete for these patients. 
Univariate analysis was conducted to examine factors
associated with the identification of source patients for young
children and to investigate associations between key variables
and the identification of refuted patient pairs. Differences in
proportions were assessed with the chi-square statistic or 2-
tailed Fisher exact test. Relative risks (RR) and 95% confi-
dence intervals of point estimates were generated where
appropriate. Differences in the means of continuous data were
tested with the Wilcoxon rank-sum test when sample sizes
were small. Unless otherwise noted, p values <0.05 were inter-
preted as statistically significant differences for all statistical
tests. 
Genotypes of isolates from young children without a
known source patient were matched against the genotyping
network project database to find previously unidentified adult
TB patient(s) whose genotype matched the child’s. Since the
sentinel study sites represented geographically dispersed states
that did not necessarily share a common border, genotype
matches were limited to patients from the same site.
To better describe the unique characteristics of patients
who transmit TB to young children, source patients (in con-
firmed patient pairs) who transmitted TB to young children
were compared with those who transmitted to adolescents or
adult patients. Since source patients who infected children 5
years of age or older may be very similar to source patients
who infected children newly born to 4 years of age, two differ-
ent comparison groups were identified 1) source patients forTUBERCULOSIS GENOTYPING NETWORK
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all secondary patients >5 years of age and 2) source patients
for secondary patients >15 years of age (excluding source
patients that transmitted to children 5–14 years of age).
Results
Characteristics of Children with TB
From 1996 to 2000, a total of 15,035 TB patients were
reported from the seven sentinel surveillance sites; 11,923
(79%) were culture confirmed, and isolates from 10,752 (90%)
culture-confirmed patients were genotyped. Of all patients in
the study, 518 (3%) patients were <5 years of age. Culture was
attempted in 270 (52%) patients <5 years of age, and 122
(45%) of these patients were culture confirmed. Isolates from
114 (93%) culture-confirmed children <5 years of age were
genotyped. 
Texas and California sites reported 73 (60%) of the 122
culture-confirmed patients <5 years of age; the Michigan and
New Jersey sites reported 18 patients each, and the remaining
three sites reported <6 patients each. Most (65%) of the study
patients were <2 years of age, and 49% were girls. Forty-three
percent were black, non-Hispanic; 37% Hispanic; 15% Asian;
4% white, non-Hispanic, and 2% Native-American or Alaskan
Native. Of the 11 foreign-born patients <5 years of age, 4 were
from Mexico, 2 were from Kenya, and 5 were from other
countries. Two thirds of the young children had pulmonary TB
disease, 15% had extrapulmonary disease, and 20% had both
pulmonary and extrapulmonary TB. 
With some notable exceptions, culture-confirmed patients
<5 years of age had demographic or clinical characteristics
similar to those of the 396 young children from the surveil-
lance area who were either culture-negative or did not have a
specimen collected for culture. The culture-confirmed group
was more likely to be <1 year old (RR=1.94, p=<0.001);
whereas white, non-Hispanic children (RR=0.41, p=0.02) and
those treated only by private providers (RR=0.6, p=0.002)
were underrepresented in the sample of culture-confirmed
patients. 
Suspected Source Patients for Young Children
Results of routine investigations used in identifying source
patients for culture-confirmed children <5 years of age are pre-
sented in Figure 1. Health department records were unavail-
able or lacked sufficient information about investigations of 11
patients; these records  were excluded. At least one epidemio-
logically related case was identified for 66 (59%) young chil-
dren with culture-confirmed TB; 57 (86%) patients had a
source patient designated, but a source could not be deter-
mined for the remaining 9 patients, although an epidemiologi-
cally related case was identified. For five of the nine patients,
multiple epidemiologically related patients (ranging from 2–11
related patients) were identified. 
To examine factors associated with the identification of
source patients for culture-confirmed children <5 years of age,
we compared young children with a suspected source patient
to patients with an unknown source of infection (Table 1).
Children <2 years of age were more likely to have a source
patient identified from routine public health investigations;
however, source patients were less frequently found for for-
eign-born children. No other statistically significant differ-
ences were found. Drug-susceptibility patterns for isolates
from young children with any drug resistance are detailed in
Table 2. 
Table 3 lists characteristics of the 53 source patients identi-
fied from public health investigations. In 41 (72%) of 57 sus-
pected patient pairs involving young children, the source
patient lived in the child’s household. Of the 16 nonhousehold
sources, 3 were babysitters, 4 were neighbors or visitors, 2
were relatives, and 1 attended the same church as the child’s
family; the specific relationship was unknown for 6 patient
pairs. Eight (15%) of the source patients resulted in disease in
more than one young child (including culture-negative chil-
dren and patients outside of the study population). 
Molecular Fingerprint Data
Of the 57 culture-confirmed patients <5 years of age for
whom a source patient was identified, 91% (52) had genotyp-
ing results for both the young child and the suspected source
patient (Figure 2). Forty-four (85%) of 52 suspected patient
pairs had concordant genotypes, and 8 (15%) of 52 had discor-
dant genotypes. Young children in refuted patient pairs were
more likely to be older than those in confirmed patient pairs
(Table 4). No association between gender, ethnicity, or for-
eign-born status of patients and the identification of refuted
patient pairs was found. Nearly three quarters (37 of 52) of
suspected patient pairs lived in the same household; however,
Figure 1. Results of public health investigations for culture-con-
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5 (14%) of these patient pairs had discordant genotypes. Sus-
pected patient pairs with differing drug-susceptibilities were
not associated with discordant genotypes; all three patient
pairs with differing drug resistance patterns had concordant
genotypes (Table 5).
For the nine young patients who had at least one epidemio-
logically related patient identified by public health investiga-
tions but for whom the source patient could not be determined,
genotyping patterns from the isolates of the epidemiologically
related cases and the young child were identical, almost with-
out exception. The only two discordant genotypes were in
young children with a single related case, not among the five
young children with multiple related patients.
Genotyping also identified patients in the local surveillance
site who had the same genotype as young children without an
identified source patient. Isolates were genotyped from 40 of
45 patients <5 years of age without a known source patient. Of
these genotyped isolates, 23 (58%) matched the strain from at
least l adult pulmonary TB case in the local surveillance site.
For most young children (13 [57%] of 23) without an identified
source patient, at least 5 adult pulmonary TB patients with gen-
otypes matching the child’s were identified. We found a wide
range in the number of adult patients (2–128) with genotypes
matching the genotypes of these young children.
Confirmed Source Patients for 
Children, Adolescents, and Adults
To better characterize the unique attributes of patients who
transmit TB to young children, characteristics of their source
patients (in confirmed patient pairs) were compared with those
for adults and adolescents. No significant differences were
found when the comparison group for this analysis consisted
of all sources to secondary patients >5 years of age or when
the comparison group was limited to sources to secondary
patients >15 years of age. The results of the latter comparison
are presented. More than 60% (354 of 584) of the suspected
patient pairs in which the secondary patient was not a child
were genotyped, and 240 (68%) of these patient pairs had con-
cordant genotypes (Figure 2). The likelihood of identifying
patient pairs with discordant genotypes was more than two
times higher among suspected patient pairs involving second-
ary patients >15 years of age than for those involving young
Table 1. Factors associated with identifying source patients for culture-confirmed tuberculosis in children <5 years of agea
Characteristics
Suspected sources identified
n=57 (%)
No suspected source identified
n=45 (%)
Relative risk
(95% CI) p value
Age ≤ 2 yrsb 44 (77) 20 (45) 1.96 (1.23 to 3.12) 0.001
Female 30 (53) 21 (47) NS
Race or ethnicity NS
Black, non-Hispanic 26 (46) 19 (42)
Hispanic 23 (40) 12 (27)
Asian 5 (9) 11 (24)
White, non-Hispanic 1 (2) 3 (7)
Native American or Alaskan Native 2 (4) 0 (0)
Foreign-bornc 1 (2) 7 (16) 0.21 (0.03 to 1.31) 0.02
Type of disease NS
Pulmonary only 40 (70) 30 (67)
Extrapulmonary only 5 (9) 8 (18)
Pulmonary and extrapulmonary 12 (21) 7 (16)
Provider typed NS
Health department 17 (31) 10 (23)
Private provider 18 (33) 21 (49)
Both 20 (36) 12 (28)
Directly observed therapye 46 (85) 28 (68) NS
Drug-resistant isolatef 6( 1 1 )8( 1 6 ) N S
aNS, not significant; CI, confidence interval.
bAge at start of treatment. Excludes one child whose date of treatment was unknown.
cExcludes one child whose birthplace was unknown.
dExcludes four children whose provider type was unknown.
eCompared to patients on self-administered therapy. 
fDrug resistance on initial testing of isolate; resistance to at least one of the following: isoniazid, rifampin, ethambutol, pyrazinamide, streptomycin, and ethionamide. Testing results 
for one or more drugs could have been unknown or not done. Excludes two children for whom drug-susceptibility testing was not done.TUBERCULOSIS GENOTYPING NETWORK
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children (32% vs. 15% discordant genotypes) (RR=2.09,
p=0.01). 
Univariate associations between source patient characteris-
tics and transmission to young children were assessed (Table
6). Although the mean age for sources to secondary patients <5
years of age was slightly lower than the mean age of sources to
the comparison group, these differences were not significant
(p=0.06; Wilcoxon test). For this population, confirmed source
patients to young children were more likely to be foreign-born
(p=0.02), Hispanic (p<0.001), a household member (p<0.001),
and not receiving directly observed therapy (p<0.01) as com-
pared with sources for adolescents and adults.
Discussion
Despite the continued decline in the number of TB patients
in the United States, ongoing TB transmission persists in many
communities. For public health agencies, TB in young chil-
dren signals recent transmission and missed opportunities for
TB prevention. In this investigation, molecular tools were used
in conjunction with information from conventional public
health investigations to better understand issues related to the
identification of source patients for young children.
In this multisite study, 57 (51%) of 111 culture-confirmed
patients <5 years of age had a source patient identified by rou-
tine investigations. Although this finding is comparable to the
frequency of source patient identification reported for other
subpopulations of children with TB (8,10–11), the finding may
be lower than anticipated for a sample of young children pre-
dominantly born in the United States. Children <2 years of age
and those born in the United States were more likely to have a
source patient found than children without these characteris-
tics. These results corroborated findings from a study of chil-
dren <5 years of age with TB in California, which
demonstrated that the source of infection is more likely to be
identified for children who were found in a contact investiga-
tion, born in the United States, <1 year of age, or black (9).
Children <5 years of age with an unknown source of infec-
tion composed a substantial proportion of the study population
(41%), a finding that underscores shortcomings in identifying
all contacts of infectious patients. While molecular data alone
are not enough to prove recent transmission, the presence of
infectious TB patients in the community who share the same
strain with a young child without a known source suggests the
possibility of casual transmission. Other impediments in iden-
tifying source patients may include barriers in completing con-
tact investigations, delays in evaluation, and problems in
identifying source patients who reside outside the health
department’s jurisdiction (27). Eighty-four percent of young
children without a source patient in this study were born in the
United States; this observation is likely to underestimate the
contribution of the global TB epidemic, because TB surveil-
lance systems in the United States do not routinely monitor the
birthplace or travel history of parents or guardians, factors pre-
Table 2. Drug-resistent patterns for isolates from culture-confirmed 
patients <5 years of age with and without a suspected source patient 
identifieda
Suspected source patient identified Source patient not identified
Ethionamide Isoniazid
Streptomycin Streptomycin 
Streptomycin Streptomycin 
Isonazid, streptomycin Pyrazinamide
Isonazid, streptomycin Pyrazinamide
Isonazid, rifampin, ethambutol streptomycin Isoniazid, streptomycin
Isoniazid, rifampin 
Isoniazid, ethambutol, 
streptomycin
aThrough routine public health investigations.
Table 3. Demographic, clinical, and risk characteristics of 53 source 
patients with tuberculosis (TB) identified from public health investiga-
tionsa
Source patient characteristics No. (%)
Age group, yrs
15–24 11 (21)
25–44 28 (53)
45–64 10 (19)
65+ 4 (8)
Female 24 (45)
Race or ethnicity
Black, non-Hispanic 22 (42)
Hispanic 24 (45)
Asian 5 (9)
Native American or Alaskan Native 2 (4)
Foreign-bornb 27 (51)
Bacteriologic results, sputum
Smear positive/culture positive 42 (79)
Smear positive/culture negative 1 (2)
Smear negative/culture positive 8 (15)
Smear not done/culture not done 2 (4)
Cavitary chest radiographc 33 (63)
Provider type
Health department 31 (58)
Private provider 11 (11)
Both 11 (11)
Directly observed therapyd 47 (71)
Previous diagnosis of TB 5 (9)
Drug-resistant isolatee 5 (9)
aThree source patients were identified as the source of infection for more than one cul-
ture-confirmed patient who was <5 years of age in the sentinel study population; two 
source patients transmitted to two children, and one transmitted to three children.
bCountry of origin was Mexico for 14 (26%) of the foreign-born patients.
cResults unknown for one patient.
dCompared to patients on self-administered therapy. 
eDrug resistance on initial testing of isolate; resistance to at least one of the following: 
isoniazid, rifampin, ethambutol, pyrazinamide, streptomycin, and ethionamide. Testing 
results for one or more drugs could have been unknown or not done. Excludes one 
source patient for whom drug susceptibility testing was not done.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1221
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viously identified as significant predictors for pediatric TB
(28,29).
Of particular concern is the finding that 16 (14%) of 111
young children with culture-confirmed TB had more than one
epidemiologically related TB source identified. This finding
indicates that a substantial number of children have multiple
TB exposures that need to be carefully assessed. For most, the
source of infection was ascertained and later confirmed by
genotyping analysis. When multiple epidemiologically related
patients existed, but none was identified as the source patient,
genotyping analysis did not provide added benefit since the
related patients were more likely to have the same genotype. 
Clinicians and TB-control programs often rely on the drug-
susceptibility results of the suspected source patient to guide
the treatment of the child since specimens for culture are not
frequently collected from children (14). Previous studies by
Steiner et al. reported 93% to 96% concordance of drug-sus-
ceptibility patterns of TB isolates from children <15 years of
age and their source (30,31), comparable to the 93% drug-sus-
ceptibility concordance among suspected patient pairs in our
study population. All suspected patient pairs with discordant
drug-susceptibility results were among patient pairs with con-
Figure 2. Comparison of genotypes for isolates from suspected source
and secondary patient pairs identified through public health investiga-
tions, 1996–2000. Children <5 years of age with culture-confirmed TB
and their sources are compared with patients >15 years of age with cul-
ture-confirmed TB and their sources.
Table 4. Characteristics of refuted and confirmed patients pairsa 
Refuted patient 
pairs (n=8) (%)
Confirmed patient 
pairs (n=44) (%)
Characteristics of young children
Mean age, monthsb 16 13
Female 4  (50) 23 (52)
Race or ethnicity
Black, non-Hispanic 5 (63) 20 (45)
Hispanic 3 (38) 16 (36)
Asian 0 (0) 5 (11)
White, non-Hispanic 0 (0) 1 (2)
Native American/Alaskan Native 0 (0) 2 (5)
Foreign-born 1 (13) 0 (0)
Source patient characteristics
Mean age, yrs 25 31
Female 6 (75) 18 (41)
Race or ethnicity
Black, non-Hispanic 5 (63) 20 (45)
Hispanic 3 (38) 17 (39)
Asian 0 (0) 5 (11)
Native American or Alaskan Native 0 (0) 2 (5)
Foreign-born  3 (38) 20 (45)
Case-patient characteristics
Shared household 5  (63) 32 (73)
Discordant drug susceptibilitiesc  0 (0) 3 (7)
Different race or ethnicity  0 (0) 1 (2)
aFor tuberculosis patients <5 years of age and their suspected source patients. Refuted 
patient pairs are suspected patient pairs with discordant genotypes; confirmed patient 
pairs are suspected patient pairs with concordant genotypes.
bWilcoxon rank-sum test: p=0.03.
cExcludes two patient pairs in which the children had drug-resistant Mycobacterium 
tuberculosis strains (streptomycin and ethambutol resistance, respectively), but suscepti-
bility results were not done for the identified source patient.
Table 5. Comparison of drug-susceptibility and genotyping results for isolates of suspected patient pairsa with any drug resistance
Source-patient isolate
Secondary patient isolate
(children <5 years of age)
Drug-susceptibility comparison
(patient pairs)
Genotype comparison
(patient pairs)
Isoniazid Isoniazid, streptomycin Discordant Concordant
Isoniazid, rifampin Isoniazid, rifampin, ethambutol, streptomycin Discordant Concordant
Streptomycin Pan-susceptible Discordant Concordant
Streptomycin Streptomycin Concordant Concordant
Isoniazid, streptomycin Isoniazid, streptomycin Concordant Concordant
Pan-susceptibleb Ethionamide Undeterminedc Concordant
Not done Streptomycin Undetermined Undetermined
aTuberculosis patients <5 years of age and their suspected source patients.
bIsolate from source patient was not tested for ethionamide resistance.
cUndetermined, results unknown for one or both patients.TUBERCULOSIS GENOTYPING NETWORK
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cordant genotypes, indicating the value of drug-susceptibility
results in young children, even when genotyping results are
known to the local health department.
The high frequency (85%) of concordant genotypes among
young children and their source patients represents good news
for public health agencies; when a potential source of infection
was identified in this population, it was most often accurate.
However, for as many as 15%, the true source was not identi-
fied and presumably could have contributed to the further
spread of disease in the community. Because young children
may have more limited opportunities for exposure than older
children, we anticipated that the frequency of confirmed
patient pairs would be associated with young age. We also
speculated that foreign-born children, especially those from
high TB-prevalence areas, might have an increased risk of
being involved in a refuted patient-pair. These children might
have had multiple opportunities for exposure to active TB
before entering the United States, which may increase the
possibility that the source of infection could have been some-
one other than the suspected source patient. However, this
potential association could not be assessed because our sample
of foreign-born children with culture-confirmed TB was small. 
The increased likelihood of concordant genotypes among
suspected patient pairs involving young children as compared
with suspected patient pairs that did not include children (85%
vs. 68%) may be explained by a number of factors, including
the greater number of casual contacts with whom adults inter-
act, biases in the case-finding practices for these groups, and
potential for coincidental reactivation of a latent TB infection
in older patient pairs. Source patients who transmitted TB to
young children were more likely to be Hispanic, foreign-born,
a household member, and not receiving directly observed ther-
apy as compared to sources for adolescents or adults. The lat-
ter may indicate nonadherence of source patients to drug
treatment and corroborates an observation by Kimerling et al.
(32). However, additional data are needed to determine the
confounding factors, including site-to-site variance, that may
affect which source patients receive directly observed therapy,
as discussed in the limitations that follow. 
A key limitation in this study was the inability to assess the
effect of potential confounding factors, such as differences in
case-finding methods (i.e., if patients were identified through
contact investigation, source patient investigations, or screen-
ing activities) on the outcome of interest (i.e., identification of
source patients or confirmed patient pairs). These data repre-
sented the sites’ routine public health practices and policies,
since uniform policies for public health investigations were
not instituted, and potential systematic variances across sites
were not ascertained by the project. In addition, analysis of
epidemiologic investigations for infectious patients in the
community who shared the same TB strain as the young child
but were not identified from routine public health investiga-
tions was outside the scope of this paper. A follow-up investi-
gation to find epidemiologic connections among patients
currently linked by genotyping results alone may provide
important data regarding potential missed opportunities in this
group. Finally, the predictive value of a discordant genotype
result is not yet known. Although study protocols instituted
quality-control measures across genotyping laboratories, a
subset of isolates from suspected patient pairs who were deter-
mined to have discordant genotypes might include TB strains
that are potentially the same. Thus, the proportion of discor-
dance observed in this study may represent an overestimate of
the actual frequency of suspected patient pairs with discordant
genotypes. 
This study highlights the challenges in identifying the
sources of infection for children under 5 years of age with cul-
ture-confirmed TB and potential weakness in our current TB-
control and prevention practices in this population. Although
contact and source patient investigations are central to any TB-
control strategy, the usefulness of these activities in identifying
Table 6. Characteristics of source patients in confirmed patient pairsa 
Source patient characteristics
Confirmed sources 
for secondary 
patients <5 yrs of 
age (n=44) (%)
Confirmed sources 
for secondary 
patients >15 ys of 
age (n=240) (%)
Mean age, yrs 31 38
Female 18 (41) 103 (43)
Race or ethnicityb
Black, non-Hispanic 20 (45) 148 (62)
Hispanic 17 (39) 23 (10)
Asian 5 (11) 19 (8)
White, non-Hispanic 0 48  (20)
Native American or Alaskan Native 2 (5) 2 (1)
Foreign-bornc 20 (45) 56 (23)
Bacteriologic results, sputumd
Smear positive/culture positive 34 (81) 200 (85)
Smear negative/culture positive 8 (19) 33 (14)
Smear negative/culture negative 0 1  (<1)
Cavitary chest radiographe 27 (64) 125 (53)
Provider typef
Health department 25 (57) 141 (60)
Private provider 9 (20) 43 (18)
Both 10 (23) 52 (22)
Directly observed therapy b,g 30 (68) 198 (84)
Previous diagnosis of TBh 6 (14) 27 (11)
Shared household with 
secondary case-patient b,i
32 (91) 116 (50)
aConfirmed patient pairs include source patients who transmitted TB to young children 
and source patients who transmitted TB to adolescent and adult patients.
bChi-square statistic, p<0.05.
cCountry of origin unknown for one patient.
dExcludes eight patients in whom either the culture or smear was not done.
eChest radiograph results unknown for two patients.
fProvider type unknown for four patients.
gCompared to patients on self-administered therapy only. Directly observed therapy sta-
tus unknown for six patients.
hHistory of TB unknown for two patients.
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the true source of infection in young children has not been previ-
ously evaluated for a large population of children by using
molecular methods. While indicating a high degree of concor-
dance between genotypes from young children and their identi-
fied sources, genotyping analysis also refuted some source
patients and pointed to other potential sources in the community
who were previously unsuspected. Further assessment of short-
comings in current methods to prevent transmission to children
and to identify their source of infection is warranted to ulti-
mately eliminate TB in young children in the United States. 
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